|Bid||24.50 x 1000|
|Ask||24.55 x 800|
|Day's range||24.38 - 25.75|
|52-week range||21.06 - 27.89|
|Beta (5Y monthly)||1.35|
|PE ratio (TTM)||7.58|
|Earnings date||07 Feb 2022 - 11 Feb 2022|
|Forward dividend & yield||0.52 (2.06%)|
|Ex-dividend date||09 Dec 2021|
|1y target est||28.20|
OLDWICK, N.J., January 26, 2022--AM Best has upgraded the Financial Strength Rating to A (Excellent) from A- (Excellent) and the Long-Term Issuer Credit Rating to "a" (Excellent) from "a-" (Excellent) for the life/health subsidiaries of CNO Financial Group, Inc. (headquartered in Carmel, IN) [NYSE: CNO]. These subsidiaries are referred to collectively as CNO Financial Group (CNO). Concurrently, AM Best has upgraded the Long-Term ICR to "bbb" (Good) from "bbb-" (Good) and the Long-Term Issue Cred
ELMSFORD, N.Y., January 13, 2022--NanoVibronix Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield® and PainShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced its board of directors has appointed Ms. Aurora (Rori) Cassirer and Ms. Maria (Lulu) Schroeder to serve as independent directors effective today.
CNO Financial (CNO) holds prospects to benefit investors owing to its declining costs, technological investments, a solid portfolio and strategic measures.